Sutro Biopharma
company
About
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
- 101 - 250
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- $85.40M
- Industries
- Biotechnology,Information Technology,Medical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$85.40M
Sutro Biopharma has raised a total of
$85.40M
in funding over 2 rounds. Their latest funding was raised on
Jul 26, 2018 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 26, 2018 | Series E | $85.40M | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
